The position of Medical Director will be an essential part of the clinical development team and will report to the Chief Medical Officer. The Medical Director will be responsible for the design and execution of clinical studies at Attovia. This individual will partner closely with Clinical Science, Clinical Operations, Regulatory, and other cross-functional team members to ensure the successful development of Attobody-based therapeutics. Attovia’s rapidly expanding pipeline includes multiple first-in-human and early proof-of-concept studies for immune-mediated diseases.
Attovia is creating a pipeline of biotherapeutics with initial focus immune-mediated disease. The company leverages Attobody™, a novel biologics platform, to generate small format biparatopic binders that expand the addressable target universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile than traditional approaches. We are currently progressing multiple programs across immune-mediated disease indications.
Our culture is centered around five core pillars:
We take pride in fostering a strong team and dynamic work environment, and we are seeking individuals who align with our values and contribute to a positive and impactful workplace.
Attovia is located in San Carlos, CA.
Attovia is an equal opportunity employer. All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin, veteran or disability status.

Attovia is creating a pipeline of biotherapeutics for the treatment of immune-mediated diseases. We leverage ATTOBODY™, our proprietary biologics platform, to generate potentially first-in-class and best-in-class multi-specifics.
ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of multi-specific biologics, with tunable half-life translating to the potential for quarterly or less frequent dosing in patients. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice. Learn more at www.attovia.com.